Łukasz Hajac, MD, PhD

Specialisation: clinical oncologist

Education:

• Graduated from the 14th Secondary School of the Belgian Polish Community in Wrocław.
• Graduated from the Faculty of Medicine at the Piastów Śląskich Medical Academy in Wrocław.
• Completed specialisation in clinical oncology.
• Currently specialising in palliative medicine.
• Obtained a PhD in medical sciences with honours from the Medical University of Wrocław.
• Senior assistant in the Clinical Oncology/Chemotherapy Department of the Lower Silesian Oncology Centre in Wrocław.
• Head of the Neuroendocrine Tumours Team at the Lower Silesian Oncology Centre in Wrocław
• Senior assistant at the Oncology Clinic of the SPZOZ ‘Latawiec’
• Consulting oncologist at the Marciniak Provincial Hospital in Wrocław.

Professional experience:

• Deputy Head of the Clinical Oncology/Chemotherapy Department at the Lower Silesian Oncology Centre in Wrocław
• Head of the Neuroendocrine Tumours Team at the Lower Silesian Oncology Centre in Wrocław
• Senior Assistant at the Oncology Clinic of the SPZOZ ‘Latawiec’
• Consulting oncologist at the Marciniak Provincial Hospital in Wrocław
• Deputy Head of the Clinical Oncology/Chemotherapy Department at the Lower Silesian Oncology Centre in Wrocław
  Since 2023, commencement of work at the Medfemina Health Centre

Certificates and completed courses:

• Collaboration in academic clinical research: Oncology Centre-Institute in Warsaw, Medical University of Gdańsk, Polish Colorectal Study Group, Central European Cooperative Oncology Group
• conducting commercial clinical trials: Parexel, Pierre Fabre Medicament, MSD, Pfizer Oncology, Merck Serono, and others – phases II-IV, functions: SI/PI/national coordinator
• establishment of the Neuroendocrine Tumour Team at the Lower Silesian Oncology Centre in 2018 with the aim of obtaining ENETS Centre of Excellence certification
• coordinator in the field of clinical oncology within the iPACC certificate for the Lower Silesian Oncology Centre
• member of the American Society of Clinical Oncology
• member of the European Neuroendocrine Tumours Society
• member of the EORTC operating within the Endocrine Tumours and Gastrointestinal Tract Cancers groups
• Member of the neuroendocrine tumour consultation group at the Polish Society of Clinical Oncology
• Member of the board of the Lower Silesian Branch of the Polish Oncology Society
• Regularly updated Good Clinical Practice course
• Completed course in medical law and medical record keeping
• Completed courses in effective business presentation
• Participation and active involvement in numerous conferences – ASCO/ESMO/ENETS, lecturer at PTOK conferences and the Polish Oncology Congress, among others

Scientific achievements:

• “Late complications after radiotherapy of the small pelvis due to cervical and uterine cancer” co-authors: Irena Józefowicz, Przemysław Pomianek, paper presented at the oncology and haematology session of the 9th National Conference of Medical Academy Student Research Clubs 2004 and published in the book of Student Research Clubs 44-45, ISBN 83-7055-206-4
• “Epidemiology and prevention of injuries in children” co-authors: Przemysław Pomianek, Lilianna Styka; the paper was presented at the scientific session of the National Conference on Emergency Medicine 2005 in Wrocław, won second place in the oral session, published in Advances of Clinical and Experimental Medicine 2006 Vol. 15, 6 1029–1036 ISSN 1230−025X
• “Knowledge of current first aid procedures among working people” co-authors: Przemysław Pomianek, the above paper was presented at the oral session of the national conference Faces of Emergency Medicine 2005 in Wrocław and published in the book of abstracts of the above-mentioned conference, it won third place in the oral session
• “Analysis of responses to treatment with trastuzumab in combination with chemotherapy in patients with HER2 overexpression depending on the status of ER receptors in comparison with a pilot group of patients treated with trastuzumab and aromatase inhibitors in metastatic breast cancer with ER (+) – own experience of the Chemotherapy Department” co-authors:

1. Ziemba, K. Gabalewicz, E. Filipczyk-Cisarż; presented at the oral session of the Falenty Breast Cancer Conference 2009 and published in Nowotwory Journal Of Oncology, 2009, Volume 9, Supplement 1, ISSN 0029-540X

• „Presentation of two cases of patients with HER-2 positive metastatic breast cancer treated with various chemotherapy regimens, including Trastuzumab, in whom progression-free survival was prolonged after the use of Capecitabine or Capecitabine with Lapatinib – Lower Silesian Oncology Centre, Clinical Oncology Department / Chemotherapy” co-authors: Tomasz Borowiec, MD, Aleksandra Pałamarz-Żarczyńska, MD, Emilia Filipczyk-Cisarż, MD, PhD; presented in a poster session at the national conference of the Polish Society of Clinical Oncology in 2009 and published in a book of abstracts from the above-mentioned conference
  “Effectiveness of lapatinib with capecitabine in heavily pretreated patients with metastatic breast cancer” co-authors:

1. Hudziec, E. Filipczyk-Cisarż, I. Dębicka – case study przedstawione na Patient Forum na kongresie American Society of Clinical Oncology w 2011 roku.

• “Immunohistochemical (IHC) prediction of lapatinib efficacy in HER2-positive advanced breast cancer patients.” Renata Duchnowska, Piotr Jan Wysocki, Lukasz Hajac i inni z Central and East European Oncology Journal of Clinical Oncology 2014 32:15_suppl, 639-639
• „Leczenie oktreotydem w różnych dawkowaniach rozsianego guza neuroendokrynnego – opis przypadku”, Hajac Łukasz, Onkologia w Praktyce Klinicznej 2015, tom 11, G, G9-G11
• „Leczenie rozsianego guza neuroendokrynnego oktreotydem u pacjentki z zaawansowanym wyniszczeniem oraz ograniczonym compliance — opis ” Hajac Łukasz, Onkologia w Prakyce Klinicznej 2015; 11, supl. G, G12– G14
• „Treatment targeting somatostatine receptors in disseminated neuroendocrine tumor — case ” Hajac Łukasz, Oncology in Clinical Practice 11 (2015): 6-8.
• „Hormonoterapia fulwestrantem u pacjentki z rozsiewem raka piersido ośrodkowego układu ” Hajac Łukasz, Onkologia w Praktyce Klinicznej 2015; 11, supl. I: I8–I10
• “Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients.” Duchnowska R, Wysocki PJ, Hajac Ł i inni z Central and East European Oncology Group (CEEOG). 2016 Jan 5;7(1):550-64. doi: 10.18632/oncotarget.6375. PMID: 26623720; PMCID: PMC4808017.
• “Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study.” Bujko K, Wyrwicz L, Hajac Ł i inni z Polish Colorectal Study Group. Ann Oncol. 2016 May;27(5):834-42. doi: 10.1093/annonc/mdw062. Epub 2016 Feb 15. PMID:
• „Pacjentka z guzem neuroendokrynnym trzustki leczona ” Onkologia w Praktyce Kliniccznej Edukacja 2016; supl. D: D1–D2
• „Leczenie pembrolizumabem chorego na czerniaka w stadium rozsiewu po uprzednim leczeniu interferonem alfa i ”, Hajac Łukasz Onkologia w Praktyce Klinicznej Edukacja 2017; 3, supl. D:D26–D27
• „ Nawrotowy czerniak skóry w rozsiewie do żołądka i ośrodkowego układu nerwowego, leczony inhibitorem BRAF i immunoterapią — opis przypadku.” Haus D, Hajac Ł, Kuniej T. Onkologia w Praktyce Klinicznej Edukacja 2019;5(6):418-424.
• „Anomalia tętnic wieńcowych jako rzadka przyczyna dławicy ” Paweł Gać, Bartłomiej Kędzierski, Martyna Głośna, Łukasz Hajac, Rafał Poręba. Folia Cardiologica 2019;14(5):509. DOI: 10.5603/FC.2019.0107
• „Spektakularna odpowiedź na leczenie celowane u chorej na zaawansowanego czerniaka z mutacją ” Hajac Ł,

Głośna M. Onkologia w Praktyce Klinicznej Tom 5, Supl. C (2019): 5-7.

• „Skuteczność i bezpieczeństwo współczesnej terapii nudności i wymiotów powodowanych chemioterapią i radioterapią.” Hajac Ł, Hajac M, Maciejczyk Medycyna Faktów Vol. 14 / Nr 1(50)/2021: 48-52.